Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2019Journal of Clinical OncologyOpen Access

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

HAHamzah Abu‐SbeihThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteDFDavid M. FaleckMemorial Sloan Kettering Cancer CenterBRBiagio RicciutiHarvard University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Abu‐Sbeih et al. (2019) studied this question.

synapsesocial.com/papers/69d94a919a6164e50fa3c780https://doi.org/10.1200/jco.19.01674
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010 · 15,374 citations
  2. 2Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort Studies2010 · 282 citations
  3. 3Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis1987 · 3,070 citations
  4. 4Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders2018 · 359 citations
  5. 5Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis2019 · 193 citations